MedTrace Logo

Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients

NCT07250217 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-04

No results posted yet for this study

Summary

The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.

Conditions

  • Acute Myeloblastic Leukemia

Interventions

DIAGNOSTIC_TEST

Epigenetic markers

Methylation profiles will be analyzed and DNA regions (CpG sites) that show significant differences between healthy and pathological cells from bone marrow will be identified. These regions could serve as epigenetic markers for cells from patients with LAM, if they can be used by digital PCR. These differentially methylated CpG islands will be targeted for the design of specific primer and probe pairs for use in digital PCR. The markers will then be tested in circulating free DNA from blood.

Sponsors & Collaborators

  • Institut de Recherche en Hématologie et Transplantation (IRHT)

    collaborator UNKNOWN

  • Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-13
Primary Completion
2027-12-01
Completion
2027-12-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07250217 on ClinicalTrials.gov